DTx Pharma, Inc.
siRNA therapeutic with proprietary fatty acid delivery motif targeting MSUT2 gene expression to treat tau-mediated neurodegeneration
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2017
- Latest Form D
- $100M, Mar 2021
- Total capital
- $109M
- Federal grants
- $3.1M
- 11 awards · 2019–2021
- Rank in peer group#158 of 326
- Private capital raised
- $106M
- 4 Form D · last Mar 2021
- 68 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 11 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Reversal of Tau Pathology with MSUT2 siRNA Conjugates$100K
- Private capital raisedForm D · SEC · 4th filing$100M
- Federal grantHealth and Human S · Phase I · Development of PMP22 siRNA Conjugates for Treatment of Charcot-Marie-Tooth Disease Type 1A$388K
- Federal grantHealth and Human S · Phase I · Development of PMP22 siRNA Conjugates for Treatment of Charcot-Marie-Tooth Disease Type 1A$388K
- Federal grantHealth and Human S · Phase I · Reversal of Tau Pathology with MSUT2 siRNA Conjugates$313K
- Federal grantHealth and Human S · Phase I · Reversal of Tau Pathology with MSUT2 siRNA Conjugates$213K
- Private capital raisedForm D · SEC · 3rd filing$200K
- Private capital raisedForm D · SEC · 2nd filing$5.5M
- Private capital raisedForm D · SEC · 1st filing$25K
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase I · Generation of potent, safe and deliverable human Tau targeting siRNA for treatment of Tauopathies$225K
- Federal grantHealth and Human S · Phase I · Generation of potent, safe and deliverable human Tau targeting siRNA for treatment of Tauopathies$225K
- Federal grantHealth and Human S · Phase I · Development of Conjugated Oligonucleotide Therapeutics for Neuronal Disease$301K
- Federal grantHealth and Human S · Phase I · Development of Conjugated Oligonucleotide Therapeutics for Neuronal Disease$301K
- Federal grantHealth and Human S · Phase I · Systemic Characterization of Novel Lipidated siRNA Conjugates$322K
- Federal grantHealth and Human S · Phase I · Systemic Characterization of Novel Lipidated siRNA Conjugates$322K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#158 · top 48%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Arthur T SuckowResearcherExecutive OfficerLinked by $1.5M in grants as PI
- Andrew AdamsDirectorNamed in SEC Form D filings
- Daniel BeckerDirectorNamed in SEC Form D filings
- Jeffrey FriedmanExecutive Officer, DirectorNamed in SEC Form D filings
- John T GrundyDirectorNamed in SEC Form D filings
- John RundyDirectorNamed in SEC Form D filings
Show all 9 people
- Matthew HammondDirectorNamed in SEC Form D filings
- Niki UpperExecutive OfficerNamed in SEC Form D filings
- Tim ScottDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 11- PendingCompounds Targeting PMP22 For The Treatment Of Charcot-marie-tooth DiseaseUSPTOApplication 63280773
- PendingStaggered Triple Lipid-modified Nucleic Acid CompoundsUSPTOApplication 63279270
- PendingBranched Triple Lipid-modified Nucleic Acid CompoundsUSPTOApplication 63279269
Show all 11 patent records
- Compounds Targeting PMP22 For The Treatment Of Charcot-marie-tooth DiseaseApplication 63280773Pending
- Staggered Triple Lipid-modified Nucleic Acid CompoundsApplication 63279270Pending
- Branched Triple Lipid-modified Nucleic Acid CompoundsApplication 63279269Pending
- Compounds Targeting Nrl For The Treatment Of Retinitis PigmentosaApplication 63246763Pending
- Compounds And Methods For The Treatment Of Duchenne Muscular DystrophyApplication PCTUS2020062333Pending
- Compound Comprising A Nucleic Acid And MethodsApplication PCTUS2020062358Pending
- Compounds And Methods For The Treatment Of Duchenne Muscular DystrophyApplication 62941549Pending
- Compound Comprising A Nucleic Acid And MethodsApplication 62940835Pending
- Lipid-modified Nucleic Acid Compounds And MethodsApplication PCTUS2019034724Pending
- Lipid-modified Nucleic Acid Compounds And MethodsApplication 62793597Pending
- Lipid-modified Nucleic Acid Compounds And MethodsApplication 62678013Pending
Related companies, and why
- ChromaDex Corp.Similar federal contract value in Biotech · null in contracts
- Amphista TherapeuticsSimilar federal contract value in Biotech · null in contracts
- REGENNOVA, INC.Similar federal contract value in Biotech · null in contracts
- FORE US Bio Inc.Similar federal contract value in Biotech · null in contracts
- Inflammasome Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Terns Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .